Navigation Links
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
Date:6/18/2009

    AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more
    availability than standard free drug in lung tissue, as demonstrated in a
    recent animal pharmacokinetic study.

MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP).

In a recent pivotal animal PK (pharmacokinetic) study, Zysolin(TM) delivered 300% more drug to lung tissue than free drug, when utilizing the same delivery method. This data demonstrates that Zysolin(TM) provides superior lung tissue penetration and a release profile which supports once-a-day human dosing frequency.

The study data will be presented, by invitation, to the upcoming July meeting of the Controlled Release Society Conference in Copenhagen, Denmark.

Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx commented, "As a result of this pre-clinical data, we anticipate that the demonstrated superiority over free drug availability will result in higher drug concentrations in lung tissue, enhancing clinical efficacy for VAP patients in vivo."

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The
'/>"/>

SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
6. Drug inhibits neuroblastoma blood supply in pre-clinical tests
7. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
8. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
9. Diageo Supports First Ever National We Dont Serve Teens Week
10. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
11. Discovery supports theory of Alzheimers disease as form of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... Javon Bea Mercy Health System ... as stroke capable by the State of Illinois, enabling ... Mercy Harvard Hospital. , The hospital was required to ... to treat stroke according to national standards of care ... patients to bypass hospitals not designated as an Emergent ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand in ... Vegas, Nevada for the annual ASD Market Week tradeshow. ... consumer-goods tradeshows and My Shiney Hiney will be one of ... Hiney can be found at booth number C1663. , My ... personal hygiene brush and cleansing system exclusively created to clean ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... of the tissue culture variety of anti-rabies vaccine, West ... the restricted nerve tissue variety vaccine till the demand-supply ... Surjyakanta Mishra told reporters here today that the Centre ... years ago citing side-effects., ,"However, since the demand-supply ...
... had affected more than 2.85 lakh population in parts of Karnataka ... , ,As against 1.20 lakh cases reported till April this ... in June so far, Minister for Health R Ashok said while ... that the government has failed to take urgent steps to contain ...
... suggests that the belief of being watched makes people behave more honestly, ... team monitored people dropping money in a canteen ... people put nearly three times more money when a poster ... poster showing flowers. , The poster might have ...
... Allison, a University of Alabama biostatistician has compiled a report ... was assisted in this venture by 19 other scientists in ... looked at more than 100 studies on the reasons for ... reasons could be an answer ,* Inadequate sleep: ...
... harassment and violence have become a way of life in ... name of combating Maoist guerrillas, say child rights activists here. ... of 36 rights organisations, says it has been urging the ... security forces from all occupied schools but to no avail. ...
... be the combination of dry eyes and mouth//, which lasts ... dry, gritty or burning eyes, intermittent blurry vision, a dry ... glands. The parotids are a pair of salivary glands behind ... and symptoms may include dry skin or vaginal dryness in ...
Cached Medicine News:Health News:Girl Students Sexually Harassed by Security Forces in Nepal 2
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the fourth quarter and full year ended ... transformative year for PTC. We are now a growing ... therapies in the rare disease space," stated Stuart W. ... are proud to bring the first treatment for Duchenne ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... and markets innovative proprietary products to treat voiding dysfunctions, ... Annual ROTH Conference on Tuesday, March 10, 2015. ... Reynolds , Chief Financial Officer, will present at 4:00 ... one at the conference at the Ritz Carlton in ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... COCOA, Fla., March 22, 2011 GeNO LLC ... technology company, today announced commencement of  the PHiano ... Treatment of Pulmonary Hypertension in patients with Pulmonary ... Idiopathic Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric ...
... MADISON, Wis., March 22, 2011 ... two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) ... predictive tool for assessing the potential cardiotoxic effects of ... transitioning into a standard supply agreement.  Moving forward, iCell ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: